Top Stories
The funds will be used to advance lead candidate STM-01 into pivotal Phase II and Phase III testing for Duchenne muscular dystrophy-associated cardiomyopathy.
The open discovery engine for protein structure prediction, design, and biological discovery is built around three releases: ESMC, ESMFold2 and ESM Atlas.
The cardio-focused biotech is seeking funding for three programmes: danicamtiv, ataciguat and tonlamarsen.
The $1.3 billion in financing from Blackstone Life Sciences positions Apogee "to achieve a self-sustainable financial profile through commercialisation of zumilokibart."
The delay comes shortly after an FDA advisory panel voted 6-3 that data from the SERENA-6 study do not support switching to camizestrant in combination with a CDK4/6 inhibitor after detection of an ESR1 mutation.
Conference News
Data from the NAVIGATE trial presented at EASL 2026 (May 27–30, Barcelona) oral presentation demonstrates belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis ...
SHANGHAI & SUZHOU, China--(BUSINESS WIRE)-- Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today...
Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASHRezdiffra improved atherogenic lipid profiles associated...
SNTX-2643 is a novel, investigational, state-selective serotonin transporter modulator being developed for anxiety disordersCompany also announces appointment of Cole Brown, M.D., as Chief Medical Off...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious di...
